Other

Cash Equivalents And Debt Securities, Available for Sale

Vertex Pharmaceuticals Cash Equivalents And Debt Securities, Available for Sale decreased by 7.5% to $2.57B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 82.1%, from $1.41B to $2.57B. Over 3 years (FY 2022 to FY 2025), Cash Equivalents And Debt Securities, Available for Sale shows a downward trend with a -27.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ1 2026
Metric ID: other_cash_equivalents_and_debt_securities_available_for_sale

Historical Data

14 periods
 Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$7.37B$7.18B$5.91B$5.64B$7.03B$5.87B$1.84B$2.16B$1.69B$1.41B$1.01B$1.22B$2.78B$2.57B
QoQ Change—-2.6%-17.7%-4.6%+24.8%-16.6%-68.7%+17.6%-21.9%-16.4%-28.2%+20.1%+128.4%-7.5%
YoY Change————-4.6%-18.3%-68.9%-61.7%-76.0%-75.9%-44.9%-43.7%+64.7%+82.1%
Range$1.01B – $7.37B
CAGR-27.7%
Avg YoY Growth-24.7%
Median YoY Growth-44.3%

Frequently Asked Questions

What is Vertex Pharmaceuticals's cash equivalents and debt securities, available for sale?
Vertex Pharmaceuticals (VRTX) reported cash equivalents and debt securities, available for sale of $2.57B in Q1 2026.
How has Vertex Pharmaceuticals's cash equivalents and debt securities, available for sale changed year-over-year?
Vertex Pharmaceuticals's cash equivalents and debt securities, available for sale increased by 82.1% year-over-year, from $1.41B to $2.57B.
What is the long-term trend for Vertex Pharmaceuticals's cash equivalents and debt securities, available for sale?
Over 3 years (2022 to 2025), Vertex Pharmaceuticals's cash equivalents and debt securities, available for sale has grown at a -27.8% compound annual growth rate (CAGR), from $7.37B to $2.78B.